Skip to main content

Table 1 Definitions of the WHO 2017 and 2010 grading classification for p-NENs and distributions of patients in the present study according to these two criteria

From: World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution

Definitions Distributions
Classification Mitotic rateA Ki-67 proliferation index (%)B Cases(%)
WHO 2017 grading criteria [7]  
Well-differentiated p-NENs:    
NET G1 < 2 < 3 150 (31.3%)
NET G2 2–20 3–20 158 (32.9%)
NET G3 > 20 > 20 64 (13.3%)
Poorly-differentiated p-NENs:    
    NEC G3 (small cell and large cell subtypes) > 20 > 20 108 (22.5%)
WHO 2010 grading criteria [8]  
 Well-differentiated endocrine tumor, G1:    
       NET G1 < 2 < 3 150 (31.3%)
 Well-differentiated endocrine tumor, G2:    
       NET G2 2–20 3–20 158 (32.9%)
 Poorly-differentiated neoplasm: neuroendocrine carcinoma, G3 (small cell and large cell type):    
       “NEC G3” > 20 > 20 172 (35.8%)
  1. A: The mitotic rate is based on the evaluation of mitoses in 50 high power fields in areas of higher density, and is expressed as mitoses per 10 high power fields
  2. B: The Ki-67 proliferation index is based on the evaluation of ≥500 cell in areas of higher nuclear labeling (hot spot)
  3. Abbreviation: WHO World Health Organization; p-NENs Pancreatic neuroendocrine neoplasms; NET Neuroendocrine tumors; NEC Neuroendocrine carcinoma; G Grading